当前位置: X-MOL 学术Alzheimer Dis. Assoc. Disord. › 论文详情
Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)
The Association Between Circulating Inflammatory Markers and the Progression of Alzheimer Disease in Norwegian Memory Clinic Patients With Mild Cognitive Impairment or Dementia.
Alzheimer Disease & Associated Disorders ( IF 2.1 ) Pub Date : 2019-08-16 , DOI: 10.1097/wad.0000000000000342
Josje Hazen 1 , Maria Vistnes 2, 3 , Maria L Barca 4, 5 , Rannveig S Eldholm 6, 7 , Karin Persson 4, 5 , Anne Brækhus 4, 5, 6 , Ingvild Saltvedt 7, 8 , Geir Selbæk 4, 9, 10 , Knut Engedal 4, 5 , Anne-Brita Knapskog 5
Affiliation  

OBJECTIVE Neuroinflammation may play an important role in the pathogenesis and progression of Alzheimer disease (AD). The aim of the present study was to detect whether increased inflammatory activity at baseline could predict cognitive and functional decline in patients with amnestic mild cognitive impairment (aMCI) or AD dementia after 2 years. METHODS Serum samples from 242 memory clinic patients with an aMCI (n=88) or AD dementia (n=154) were analyzed for C-reactive protein and for 14 other inflammatory markers [interleukin (IL)-1β, interleukin-1 receptor antagonist, IL-6, IL-10, IL-12p40, IL-17a, IL-18, IL-22, IL-33, tumor necrosis factor, cluster of differentiation 40 ligand, interferon-γ, chemokine ligand (CCL) 2, and CCL4] by bead-based multiplex immunoassay. Disease progression was measured by the annual increase in the Clinical Dementia Rating Scale Sum of Boxes (CDR-SB) and annual decrease in the score on the Mini-Mental State Examination (MMSE). RESULTS No association between increased levels of the inflammatory markers and change on the CDR-SB or MMSE score was found, but there was a significant difference in baseline IL-6 and interleukin-1 receptor antagonist levels between aMCI and AD dementia groups. CONCLUSION Increased levels of inflammatory markers were not associated with faster progression as measured by the annual change on the CDR-SB or MMSE score.

中文翻译:

挪威轻度认知障碍或痴呆患者的循环炎症指标与阿尔茨海默氏病进展之间的关系。

目的神经炎症可能在阿尔茨海默病(AD)的发病机理和进展中起重要作用。本研究的目的是检测基线时炎症活动增加是否可以预测2年后轻度认知障碍(aMCI)或AD痴呆患者的认知和功能下降。方法分析242例患有aMCI(n = 88)或AD痴呆(n = 154)的记忆临床患者的血清中的C反应蛋白和其他14种炎症标记[白介素(IL)-1β,白介素-1受体拮抗剂,IL-6,IL-10,IL-12p40,IL-17a,IL-18,IL-22,IL-33,肿瘤坏死因子,分化簇40配体,干扰素-γ,趋化因子配体(CCL)2,和CCL4]通过基于珠的多重免疫分析。通过临床痴呆症等级量表总和(CDR-SB)的年度增加和迷你精神状态检查(MMSE)的年度减少来衡量疾病的进展。结果未发现炎性标志物水平增加与CDR-SB或MMSE评分变化之间存在关联,但aMCI和AD痴呆组的基线IL-6和白介素1受体拮抗剂水平存在显着差异。结论炎性标志物水平的升高与CDR-SB或MMSE分数的年度变化所衡量的进展更快无关。但aMCI和AD痴呆组之间的基线IL-6和白介素1受体拮抗剂水平存在显着差异。结论如通过CDR-SB或MMSE评分的年度变化来衡量,炎症标志物水平的升高与更快的进展无关。但aMCI和AD痴呆组之间的基线IL-6和白介素1受体拮抗剂水平存在显着差异。结论炎性标志物水平的升高与CDR-SB或MMSE分数的年度变化所衡量的进展更快无关。
更新日期:2019-11-01
down
wechat
bug